Praxis Precision Medicines (PRAX)
(Delayed Data from NSDQ)
$59.88 USD
+1.18 (2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $59.85 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$59.88 USD
+1.18 (2.01%)
Updated Sep 13, 2024 04:00 PM ET
After-Market: $59.85 -0.03 (-0.05%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Zacks News
Praxis Stock Up as Epilepsy Candidate Shows Reduction in Seizures
by Zacks Equity Research
Shares of PRAX gains on positive efficacy data from the mid-stage study of its investigational candidate, relutrigine, for two epilepsy indications.
Praxis Precision Medicines (PRAX) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Praxis Precision Medicines (PRAX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Praxis Precision Medicines (PRAX) delivered earnings and revenue surprises of 26.89% and 75.14%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Atara Biotherapeutics (ATRA) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Atara Biotherapeutics (ATRA) delivered earnings and revenue surprises of -148% and 40.70%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Femasys Inc. (FEMY) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Femasys (FEMY) delivered earnings and revenue surprises of -16.67% and 55.80%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Arcutis Biotherapeutics (ARQT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
C4 Therapeutics (CCCC) Soars 13.7%: Is Further Upside Left in the Stock?
by Zacks Equity Research
C4 Therapeutics (CCCC) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
JAZZ Falls as Suvecaltamide Tremor Study Fails to Meet Goals
by Zacks Equity Research
JAZZ shares are down 5% as it fails to achieve statistical significance on the primary and key secondary endpoint in a mid-stage tremor study on suvecaltamide.
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Praxis Precision Medicines (PRAX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Regenxbio (RGNX) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Regenxbio (RGNX) delivered earnings and revenue surprises of -7.81% and 37.77%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Agenus (AGEN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Agenus (AGEN) delivered earnings and revenue surprises of 15.08% and 31.19%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
by Zacks Equity Research
The consensus price target hints at a 144.7% upside potential for Praxis Precision Medicines (PRAX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
by Zacks Equity Research
Praxis Precision Medicines (PRAX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
by Ekta Bagri
Praxis Precision Medicines, Inc. (PRAX) and Viking Therapeutics, Inc. (VKTX) gain from positive study updates.
Praxis (PRAX) Surges on Positive Epilepsy Study Results
by Zacks Equity Research
Praxis (PRAX) reports strong response rates across both study arms in a phase IIa proof of concept study for epilepsy patients with PPR.
What Makes Praxis Precision Medicines, Inc. (PRAX) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does Praxis Precision Medicines, Inc. (PRAX) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts Think Praxis Precision Medicines, Inc. (PRAX) Could Surge 134.35%: Read This Before Placing a Bet
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 134.4% in Praxis Precision Medicines, Inc. (PRAX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Praxis Precision Medicines, Inc. (PRAX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Praxis Precision Medicines, Inc. (PRAX) delivered earnings and revenue surprises of 5.71% and 71.67%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Praxis Precision Medicines, Inc. (PRAX) Upgraded to Strong Buy: Here's What You Should Know
by Zacks Equity Research
Praxis Precision Medicines, Inc. (PRAX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Praxis Precision Medicines, Inc. (PRAX) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Wall Street Analysts Believe Praxis Precision Medicines, Inc. (PRAX) Could Rally 494.95%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Praxis Precision Medicines, Inc. (PRAX) points to a 495% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Praxis Precision Medicines, Inc. (PRAX) Loses -32.03% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
by Zacks Equity Research
The heavy selling pressure might have exhausted for Praxis Precision Medicines, Inc. (PRAX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Best Momentum Stocks to Buy for October 11th
by Zacks Equity Research
PBF, PRAX and CPRX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 11, 2023.
New Strong Buy Stocks for October 11th
by Zacks Equity Research
PBF, PRAX, CPRX, MFA and GFF have been added to the Zacks Rank #1 (Strong Buy) List on October 11, 2023.
Praxis (PRAX) Tanks on Negative Data From Depression Study
by Zacks Equity Research
Praxis (PRAX) posts negative data from the phase II/III Aria study that evaluated PRAX-114 for monotherapy treatment of major depressive disorder. Shares fall.